Tikkanen M J
Department of Medicine, Helsinki University Central Hospital, Finland.
Curr Opin Lipidol. 1995 Dec;6(6):360-4. doi: 10.1097/00041433-199512000-00005.
A wide consensus has been reached concerning the importance of lipid-lowering drug therapy in patients with dyslipidaemia with overt coronary heart disease. This consensus is also likely to be reflected in the more active treatment of other high-risk patient groups. The statin family of drugs has been tested in a large secondary prevention study, the Scandinavian Simvastatin Survival Study, and in angiographic trials. Their role in the treatment of hypercholesterolaemia and mixed hyperlipidaemia is increasing, whereas fibrates are increasingly limited to hypertriglyceridaemia.
关于降脂药物治疗在患有明显冠心病的血脂异常患者中的重要性已达成广泛共识。这一共识也可能体现在对其他高危患者群体更积极的治疗中。他汀类药物已在一项大型二级预防研究——斯堪的纳维亚辛伐他汀生存研究以及血管造影试验中进行了测试。它们在治疗高胆固醇血症和混合性高脂血症中的作用日益增强，而贝特类药物则越来越多地局限于治疗高甘油三酯血症。
